Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a fellow of the AACR Academy.

Two leading cancer organizations are calling for regulation of e-cigarettes and other electronic nicotine delivery systems (ENDS).

A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.

A team of biomedical engineers has developed a new "tumor-in-a-dish" technology that promises to improve the effectiveness of chemotherapy.

There are now approximately 14.5 million cancer survivors in the United States, thanks in large part to advances in cancer research and the development of new anti-cancer therapies.

Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.

Despite a challenging health care landscape, Vanderbilt University Medical Center continues to advance the highest-quality patient care, train the next generation of physician leaders and push forward the frontiers of biomedical science.